Apellis Pharmaceuticals Stock In The News
| APLS Stock | USD 24.14 0.01 0.04% |
Our overall analysis of Apellis Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Apellis Pharmaceuticals. The specific impact of Apellis Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Apellis Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Apellis Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Apellis Pharmaceuticals Backtesting and Apellis Pharmaceuticals Hype Analysis. For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Apellis and other traded companies coverage with news coverage. We help investors stay connected with Apellis headlines for the 22nd of March to make an informed investment decision based on correlating the impacts of news items on Apellis Stock performance. Please note that trading solely based on the Apellis Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Apellis |
Apellis Pharmaceuticals Today Top News and Investor Outlook
Apellis Pharmaceuticals Past News Timeline
Apellis Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Apellis earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Apellis Pharmaceuticals that are available to investors today. That information is available publicly through Apellis media outlets and privately through word of mouth or via Apellis internal channels. However, regardless of the origin, that massive amount of Apellis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Apellis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Apellis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Apellis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Apellis Pharmaceuticals alpha.
Apellis Largest EPS Surprises
Earnings surprises can significantly impact Apellis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-01 | 2024-06-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2024-05-07 | 2024-03-31 | -0.47 | -0.42 | 0.05 | 10 | ||
2018-04-30 | 2018-03-31 | -0.33 | -0.43 | -0.1 | 30 | ||
2025-02-25 | 2024-12-31 | -0.4019 | -0.29 | 0.1119 | 27 | ||
2018-03-19 | 2017-12-31 | -0.48 | -0.6 | -0.12 | 25 | ||
2018-07-31 | 2018-06-30 | -0.47 | -0.61 | -0.14 | 29 |
Apellis Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Apellis Pharmaceuticals Stock. Current markets are strongly bearish. About 79% of major world exchanges and indexes are down. See today's market update for more information.
18th of March 2025
JP Morgan Cut Apellis Price Forecasts, Cites Longer Peak Sales Timing For Syfovre at benzinga.com
12th of March 2025
Victory Capital Management Inc. Purchases 150,363 Shares of Apellis Pharmaceuticals, Inc. ... at news.google.com
6th of March 2025
The Goldman Sachs Group Cuts Apellis Pharmaceuticals Price Target to 32.00 at thelincolnianonline.com
5th of March 2025
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset JP Morgan Analyst at finance.yahoo.com
4th of March 2025
Disposition of 6667 shares by Watson David O. of Apellis Pharmaceuticals subject to Rule 1... at MacroaxisInsider
28th of February 2025
Apellis Pharmaceuticals GAAP EPS of -0.29 beats by 0.10, revenue of 212.5M beats by 14.59M at seekingalpha.com
20th of February 2025
Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli ... at globenewswire.com
4th of February 2025
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 at gurufocus.com
23rd of January 2025
Apellis Pharmaceuticals, Inc. General Counsel David O. Watson Sells 3,323 Shares at thelincolnianonline.com
Apellis Pharmaceuticals Investors Sentiment
The influence of Apellis Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Apellis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Apellis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Apellis. The trend in average sentiment can be used to explain how an investor holding Apellis can time the market purely based on public headlines and social activities around Apellis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Apellis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Apellis Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Apellis Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Apellis Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Apellis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Apellis Pharmaceuticals' short interest history, or implied volatility extrapolated from Apellis Pharmaceuticals options trading.
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.